Clinical analysis of recombinant human granulocyte colony stimulating factor in the treatment of breast cancer after chemotherapy

Abstract

Objective To observe the effect of recombinant human granulocyte colony stimulating factor (rhG-CSF) on bone marrow depression after chemotherapy in breast cancer patients. The effects of different doses of rhG-CSF were observed. The necessity of using rhG-CSF in the treatment of different chemotherapy cycles was observed. Methods Retrospective survey method was used, screening for breast cancer at least three cycles of TEC regimen and 24-48 h after chemotherapy with rhG-CSF 150 μg or 300 μg 5 days as treatment group, rhG-CSF was not given as the control group. In reducing blood and febrile neutropenia were observed before and after the first chemotherapy cycle and three cycles of chemotherapy (febrileneutropenia, FN) incidence rate, and carries on the statistical analysis to the index. Results The total number of white blood cells and neutrophils in the treatment group after chemotherapy were higher than those in the control group, the incidence of FN was lower than that of the control group, and the differences were significant (P 0.05). There was no significant difference in the effects of different doses of rhG-CSF (P>0.05) on the reduction of WBC, granulocyte and FN in the same chemotherapy cycle.In the first chemotherapy cycle of control group, the incidence of FN was significantly lower than that in the third cycle of control group, the difference was significant (P<0.05). Conclusions rhG-CSF in the prevention of bone marrow suppression after breast cancer surgery and chemotherapy induced by the combination of paclitaxel and the treatment of the patients has good curative effect. rhG-CSF is recommended for low dose prevention, to prevent the use of rhG-CSF after chemotherapy in patients with multiple chemotherapy. Key words: Recombinant human granulocyte colony stimulating factor; Breast cancer; Chemotherapy; Febrile neutropenia febrile neutropenia